Please login to the form below

Not currently logged in

Achieving remission

An international media relations case study into a new treatment approach for rheumatoid arthritis

RoACTEMRA / ACTEMRA was successfully established pre-launch as a promising new treatment approach for rheumatoid arthritis, based on its unique mode of action (MOA). As anticipation grew, an intelligent media strategy was required, to craft a brand story and differentiate it in a rapidly growing marketplace. This required an intelligent shift in communications from MOA to reason to prescribe, to patient benefits. A combination of data releases and creative digital outreach at high-profile rheumatology congresses enhanced a traditional communications programme, providing a platform to build a strong story for RoACTEMRA / ACTEMRA during its launch year.


The unique mode of action targeted the chemical messenger responsible for pain
The unique mode of action targeted the chemical messenger responsible for pain


• Tumour necrosis factor (TNF) inhibitors are dominant, having been on the market for 10 years. Extensive clinical experience of these treatments makes it difficult to introduce new therapies with different mode of actions
• Opportunities for new entrants to communicate data are limited to congresses, leading to intense competition for share of voice (SOV)
• Pre-launch communications for RoACTEMRA / ACTEMRA highlighted a unique mode of action. Towards launch, emphasis was needed to give strong rationale for prescribing.

Taking a leadership position and communicating beyond the congress room meant RoACTEMRA / ACTEMRA could be positioned as a realistic first-choice option with strong efficacy and safety, rather than merely a promising candidate.

• Global brand vocabulary ensured all external communications were consistent with key messages
• Key journalists were targeted with a media outreach programme to deliver coverage with influence
• Roche Twitter profile issued congress tweets, providing influencers with the opportunity to respond quickly and drive conversation online
• Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations
• Close collaboration with investor relations increased interest beyond medical media
• 'Realising the goal of remission' media briefing held at EULAR 2009
• Media attendees provided with a bespoke suite of press materials, developed to accommodate different audiences
• Onsite media interviews scheduled with KOLs involved in clinical trials.

• Increase ACR 2009 media SOV by >10 per cent compared to ACR 2008 (50 per cent).  RoACTEMRA / ACTEMRA generated a 16 per cent increase in media share of voice to 66 per cent, compared to the second highest competitor share of 16 per cent
• Position RoACTEMRA / ACTEMRA as the treatment offering patients the best chance of long-lasting remission. "Patients treated with RoACTEMRA / ACTEMRA achieve consistently high remission rates which increase over time" (86 per cent articles)
• Attendance of >20 journalists at press briefing. Attendance of 30 journalists from 13 countries
• Create rapid response channel for RoACTEMRA / ACTEMRA's media communications. 33 re-tweets and 74 unique online posts created
• Direct reach to >2,000 online influencers. Twitter communications reached 22,361 influencers.

Client verdict
"The team's intelligent and strategic thinking has helped us shape a story that differentiates RoACTEMRA / ACTEMRA from its competitors, maintaining a consistently high level of media interest prior to and during its launch year. This is reflected in the excellent results achieved."
Peter Bayliss, head of global inflammation communications, F. Hoffmann-La Roche.

Communiqué Awards 2010
RoACTEMRA/ACTEMRA: Reaching beyond the boundaries of existing treatmentsfor was highly commended for Excellence in Healthcare Communications using Media Relations (International) at the Communiqué Awards 2010.


Case study details

Client: F. Hoffman-La Roche
Agency: Cohn & Wolfe
Campaign: RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments
Timescale: 2008 to 2009

19th August 2010


Subscribe to our email news alerts

Featured jobs


Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...